Patents Examined by Golam M M Shameem
  • Continuous processes for hydrolyzing hemicelluloses from ligocellulosic materials with cleaning system
    Patent number: 9435002
    Abstract: A continuous process for producing hemicellulose sugars from a biomass extraction liquor is provided. A system is configured for continuously producing hemicellulose sugars and/or hemicellulose derivatives from a biomass extraction liquor, the system comprising at least a first hydrolysis reactor and a second hydrolysis reactor. Each of the hydrolysis reactors is in switchable communication with (i) an operating feed stream of a biomass extraction liquor containing water, hemicellulose oligomers, and dissolved or suspended lignin, and (ii) a cleaning feed stream of a cleaning agent selected from the group consisting of steam, an alkaline solution, an organic solvent, and combinations thereof. The cleaning agent dissolves precipitated lignin formed from the lignin under the hydrolysis reaction conditions.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: September 6, 2016
    Assignee: API Intellectual Property Holdings, LLC
    Inventors: Zheng Dang, Mehmet Sefik Tunc, Ziyu Wang
  • Process for carrying out a reaction involving a liquid reaction mixture
    Patent number: 9434708
    Abstract: In a process for carrying out a reaction, a liquid reaction mixture is contacted with a catalyst that includes silica and/or a silicate, in which process a silicon compound that is soluble in the liquid reaction mixture is added to the reaction mixture before being contacted with the catalyst. The aqueous reaction mixture suitably contains water, an alcohol or a mixture thereof.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 6, 2016
    Assignee: FURANIX TECHNOLOGIES B.V.
    Inventors: Ana Sofia Vagueiro De Sousa Dias, Jan Cornelis Van Der Waal, Etienne Mazoyer
  • Process for the preparation of enantiomeric forms of 2,3-diaminopropionic acid derivatives
    Patent number: 9434696
    Abstract: The disclosure relates to a process for the preparation of the enantiomeric forms of 2,3-diaminopropionic acid derivatives of formula I, wherein R1, R2 and R3 are defined as in the disclosure, by racemate resolution. The separation of the racemate into its enantiomers takes place through formation of diastereomeric salts upon addition of an enantiomerically pure auxiliary, and subsequent separation by fractional crystallization.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: September 6, 2016
    Assignee: Sanofi
    Inventors: Claus-Dieter Graf, Joerg Rieke-Zapp
  • Water-insoluble ruthenium catalyst composition for use in aqueous hydrogenation reactions
    Patent number: 9433937
    Abstract: The invention relates to a method for converting a precatalyst complex to an active catalyst complex, wherein the precatalyst complex and the active catalyst complex comprise a ruthenium atom and an optically active ligand that is insoluble in water, and the active catalyst complex furthermore comprises a monohydride and a water molecule. The method comprises the steps of providing water as an activation solvent system with a pH value equal or below 2, and solving said precatalyst complex, an acid, and hydrogen therein. The invention further relates to a method for manufacturing a catalyst composition, a method for hydrogenating a substrate molecule and a reaction mixture.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: September 6, 2016
    Assignee: DEXLECHEM GMBH
    Inventor: Sonja Jost
  • Process for the preparation of Clomiphene
    Patent number: 9428442
    Abstract: An improved process for the preparation of the active pharmaceutical ingredient Clomiphene and, in particular, trans-Clomiphene, using acetic acid or trifluoroacetic acid is disclosed.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: August 30, 2016
    Assignee: F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.
    Inventors: Siro Serafini, Pierluigi Padovan
  • Tethering cysteine residues using cyclic disulfides
    Patent number: 9428589
    Abstract: Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including SOD1 and DJ-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker. The covalently attached dimers exhibit increased stabilization.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 30, 2016
    Assignee: Brandeis University
    Inventors: Jeffrey N. Agar, Joseph Salisbury
  • Compounds for the treatment of hepatitis C
    Patent number: 9422311
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: August 23, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Eric P. Gillis, Paul Michael Scola
  • Pyridopyrimidine derivatives and use thereof
    Patent number: 9422298
    Abstract: The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3? OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: August 23, 2016
    Assignees: CMG Pharmaceutical Co., Ltd., Sung Kwang Medical Foundation
    Inventors: Gilnam Lee, Chul Soo Lim, Han Won Cho, Jeongbeob Seo, Albert C. Gyorkos, Suk Young Cho, Eun Kyung Choi, Choung Soo Kim, Jung Jin Hwang, Jin Sung Kim, Hee Jung An, Yong Wha Moon
  • HCV protease inhibitors and uses thereof
    Patent number: 9422333
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: August 23, 2016
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh
  • Prophylactic agent and/or therapeutic agent for diffuse large B-cell lymphoma
    Patent number: 9416131
    Abstract: To provide a medicament which shows more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-CLBCL) than the existing Btk inhibitor, and is excellent in safety. The present compound exhibits more remarkable effect in treatment of activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL) patients, inter alia, ABC-DLBCL patients having CD79B wild-type gene background than the existing Btk inhibitor, and therefore, it can attain the object of the present invention.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: August 16, 2016
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshio Yoshizawa, Ryohei Kozaki
  • Griseofulvin derivatives
    Patent number: 9416142
    Abstract: The present invention relates to compounds of the following general formula (I), or to a pharmaceutically acceptable salt thereof, as well as to the uses thereof as a drug, in particular for treating cancerous or precancerous hyperproliferative conditions, and to the pharmaceutical compositions containing same.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: August 16, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Frédéric Marion, Frédéric Lieby-Muller, Serge Grisoni, Emmannuel Fournier
  • Super lewis acidic borate esters as 18F-labeled PET probes
    Patent number: 9409927
    Abstract: Compounds having a 1-bora-1-fluoro-2,6,7-trioxabicyclo[2.2.2]octane moiety wherein the fluorine is 18F are described. Also described are reagents for radiolabeling a molecule having Formula I. Method for radiolabeling molecules with the disclosed reagents are also descried, as are radiolabeled molecules prepared thereby.
    Type: Grant
    Filed: January 24, 2014
    Date of Patent: August 9, 2016
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South Florida
    Inventors: Mark Lee McLaughlin, Haibin Tian
  • Small-molecule Hsp90 inhibitors
    Patent number: 9403828
    Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: August 2, 2016
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventor: Gabriela Chiosis
  • Process for the production of acid anhydrides from epoxides
    Patent number: 9403788
    Abstract: A method of making acid anhydrides from epoxide and carbon monoxide feedstocks is presented. In various aspects, the method includes steps of reacting the contents of a feed stream comprising an epoxide, a solvent, a carbonylation catalyst and carbon monoxide to produce a first carbonylation product stream comprising a beta-lactone, then reacting the contents of the first carbonylation product stream with additional carbon monoxide to produce a second carbonylation product stream comprising an acid anhydride, and separating at least a portion of the acid anhydride from the second carbonylation product stream to produce: i) an acid anhydride product stream comprising the separated portion of acid anhydride; and ii) a recycling stream comprising the carbonylation catalyst, and finally adding the recycling stream to the feed stream.
    Type: Grant
    Filed: February 12, 2013
    Date of Patent: August 2, 2016
    Assignee: NOVOMER, INC.
    Inventors: Han Lee, Michael A. Slowik
  • Process for the synthesis of carbonucleoside and intermediates for use therein
    Patent number: 9403864
    Abstract: Disclosed is a process for preparing a carbonucleoside of formula (1) and intermediates for use therein. The process involves the step of reacting a compound of formula (2) with a compound of formula (3) under Mitsunobu-type reaction conditions to obtain a compound of formula (4), wherein PG1, PG2, PG3 and PG4 are protecting groups. The compound of formula (4) is deprotected to form the compound of formula (1), as shown below.
    Type: Grant
    Filed: May 30, 2011
    Date of Patent: August 2, 2016
    Assignee: Alphora Research Inc.
    Inventors: Dino Alberico, Joshua Clayton, Craig Dixon, Boris Gorin
  • Anti-inflammatory compounds
    Patent number: 9403786
    Abstract: New clerodane compounds isolated from plant material from Dodonaea polyandra are disclosed. The compounds have anti-inflammatory activity. Pharmaceutical and cosmetic compositions containing the compounds, as well as methods of treating inflammation using the compounds, are also disclosed.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: August 2, 2016
    Assignees: University of South Australia, Chuulangun Aboriginal Corporation
    Inventors: Susan J. Semple, Bradley S. Simpson, Ross Allan McKinnon, David Claudie, Jacobus P. Gerber, Jiping Wang, George Moreton, Sr.
  • Substituted purinone compounds
    Patent number: 9403827
    Abstract: The invention relates to compounds of formula (I): (I) as described herein, pharmaceutical preparations comprising such compounds, uses and methods of use for such compounds in the treatment of a disorder or a disease mediated by the activity of as MDM2 and/or MDM4, and combinations comprising such compounds.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: August 2, 2016
    Assignee: NOVARTIS AG
    Inventors: Pascal Furet, Vito Guagnano, Philipp Holzer, Joerg Kallen, Robert Mah, Keiichi Masuya, Achim Schlapbach, Andrea Vaupel
  • Compositions and methods for the treatment of inflammatory disorders
    Patent number: 9403826
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing inflammatory disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of intermittent claudication resulting from obstructed arteries in the limbs, and vascular dementia, improves blood flow through peripheral blood vessels and therefore helps with blood circulation in the arms and legs (e.g.
    Type: Grant
    Filed: February 2, 2013
    Date of Patent: August 2, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Compositions and methods for the treatment of depression
    Patent number: 9399634
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: July 26, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 9394308
    Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Qingyi Li, Lily Cheng, Christopher M. Liu, Iwona E. Wrona, Blaise S. Lippa, Chester A. Metcalf, III, Andrew J. Jackson, Lauren M. Chapman